



Cardiac and Pulmonary Complications Among Lung Cancer Patients with Smoking Habits: Understanding the Interplay for Better Management.

Nootan Ramling Mali¹, Dr. Berlin Sara Thampy²

¹Research Scholar, Malwanchal University, Indore

²Research Supervisor, Malwanchal University, Indore

Introduction

Lung cancer remains one of the most prevalent and deadliest cancers worldwide, with smoking being a leading cause of its development. However, the complexities of this disease extend beyond the lungs themselves. Cardiac and pulmonary complications often arise among lung cancer patients, particularly those with a history of smoking. Understanding the interplay between lung cancer, smoking habits, and these complications is crucial for comprehensive patient care and management.

The Relationship Between Lung Cancer, Smoking, and Complications

1. Smoking as a Major Risk Factor for Lung Cancer:
 - The strong association between cigarette smoking and lung cancer has been extensively documented in medical literature.
 - Tobacco smoke contains numerous carcinogens that can initiate and promote the development of lung cancer.
 - Smokers are at a significantly higher risk of developing lung cancer compared to non-smokers, with the risk increasing with the duration and intensity of smoking.
2. Lung Cancer and Cardiovascular Complications:
 - Lung cancer and cardiovascular diseases often coexist due to shared risk factors such as smoking, aging, and inflammation.
 - Cardiovascular complications among lung cancer patients include coronary artery disease, myocardial infarction, arrhythmias, heart failure, and pulmonary embolism.
 - Both cancer itself and cancer treatments, such as chemotherapy and radiation therapy, can contribute to the development or exacerbation of cardiovascular conditions.
3. Pulmonary Complications in Lung Cancer Patients:
 - Lung cancer patients are prone to various pulmonary complications, including chronic obstructive pulmonary disease (COPD), pneumonia, pleural effusion, and lung infections.
 - Smoking-related lung damage can exacerbate pre-existing pulmonary conditions or predispose patients to new complications.
 - Lung cancer treatments such as surgery, chemotherapy, and radiation therapy can also adversely affect pulmonary function and lead to complications.

Understanding the Mechanisms

1. Shared Pathophysiology:
 - Smoking-induced inflammation and oxidative stress play key roles in the development of both lung cancer and cardiovascular/pulmonary complications.

- Chronic inflammation in the lungs can lead to tissue damage, fibrosis, and impaired pulmonary function, while also promoting atherosclerosis and endothelial dysfunction in the cardiovascular system.
 - Genetic susceptibility and individual variations in inflammatory responses further contribute to the complex interplay between these conditions.
2. Impact of Lung Cancer Treatments:
- Chemotherapy agents and radiation therapy, while essential for treating lung cancer, can have cardiotoxic and pulmonary toxic effects.
 - Chemotherapeutic drugs like anthracyclines and targeted therapies may induce cardiomyopathy, arrhythmias, or myocardial ischemia.
 - Radiation therapy targeting thoracic tumors can damage lung tissue, leading to radiation pneumonitis or fibrosis, and increase the risk of cardiovascular events due to radiation-induced vascular damage.

Clinical Implications and Management Strategies

1. Comprehensive Risk Assessment:
- Lung cancer patients with a history of smoking should undergo thorough cardiovascular and pulmonary evaluations to assess baseline function and identify pre-existing conditions.
 - Cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and smoking cessation should be addressed to minimize the risk of cardiovascular complications.
2. Multidisciplinary Approach to Treatment:
- Optimal management of lung cancer requires a multidisciplinary team approach involving oncologists, pulmonologists, cardiologists, and other specialists.
 - Treatment decisions should consider the potential impact on both cancer and cardiovascular/pulmonary health, balancing therapeutic efficacy with potential risks.
3. Monitoring and Surveillance:
- Regular monitoring of cardiac and pulmonary function during and after lung cancer treatment is essential for early detection and management of complications.
 - Imaging modalities such as echocardiography, cardiac MRI, pulmonary function tests, and imaging studies can aid in the surveillance of cardiovascular and pulmonary health.
4. Supportive Care and Lifestyle Interventions:
- Smoking cessation remains the single most effective intervention to reduce the risk of lung cancer and cardiovascular complications among smokers.
 - Pulmonary rehabilitation, exercise training, and dietary modifications can help optimize pulmonary and cardiovascular function and improve overall quality of life for lung cancer patients.

Conclusion

The intersection of lung cancer, smoking habits, and cardiovascular/pulmonary complications poses significant challenges in clinical management. Recognizing the complex interplay between these conditions is essential for providing comprehensive care to lung cancer patients. A multidisciplinary approach, encompassing risk assessment, treatment optimization, and supportive care, is crucial for mitigating the impact of cardiac and pulmonary complications and improving patient outcomes. Efforts to promote smoking cessation and lifestyle modifications are fundamental in addressing the root cause of these interconnected health issues and reducing the burden of lung cancer and associated comorbidities.

Reference

1. Dezube A.R., Jaklitsch M.T. New evidence supporting lung cancer screening with low dose CT surgical implications. *Eur. J. Surg. Oncol.* 2020;46:982–990. doi: 10.1016/j.ejso.2020.02.015
2. Hennon M., Landreneau R.J. Role of Segmentectomy in Treatment of Early-Stage Non-Small Cell Lung Cancer. *Ann. Surg. Oncol.* 2018;251:59–63. doi: 10.1245/s10434-017-5787-5.

3. Dai C., Shen J., Ren Y., Zhong S., Zheng H., He J., Xie D., Fei K., Liang W., Jiang G., et al. Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or >1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study. *J. Clin. Oncol.* 2016;34:3175–3782. doi: 10.1200/JCO.2015.64.6729
4. Saji H., Okada M., Tsuboi M., Nakajima R., Suzuki K., Aokage K., Aoki T., Okami J., Yoshino I., Ito H., et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. *Lancet.* 2022;399:1607–1617. doi: 10.1016/S0140-6736(21)02333-3
5. Altorki N.K., Wang X., Wigle D., Gu L., Darling G., Ashrafi A.S., Landrenau R., Miller D., Liberman M., Jones D.R., et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: Post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503) *Lancet. Resp. Med.* 2018;6:915–924. doi: 10.1016/S2213-2600(18)30411-9.
6. Mitchell K.G., Antonoff M.B. Encouraging early outcomes in cancer and leukemia group B (CALGB)/Alliance 140503: Patient selection, not extent of resection, is the key to perioperative success. *Ann. Transl. Med.* 2019;7((Suppl. 1)):S50. doi: 10.21037/atm.2019.03.12.
7. Cancer and Leukemia Group B 140503 (2022) A phase III randomized trial of lobectomy versus sublobar resection for small (≤ 2 cm) peripheral non-small cell lung cancer. [(accessed on 31 January 2023)]; Available online: <https://clinicaltrials.gov/ct2/show/NCT00499330>
8. Bugge A., Lund M.B., Brunborg C., Solberg S., Kongerud J. Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease. *Ann. Thorac. Surg.* 2016;101:2125–2131. doi: 10.1016/j.athoracsur.2015.12.057.
9. Qiang G., Liang C., Xiao F., Yu Q., Wen H., Song Z., Tian Y., Shi B., Guo Y., Liu D. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer. *Int. J. Chron. Obstruct. Pulmon. Dis.* 2015;11:43–49. doi: 10.2147/COPD.S97411.
10. Sihoe A.D.L. We Asked the Experts: Minimally Invasive Segmentectomy for Early Stage Lung Cancer-Will it Replace Lobectomy? *World J. Surg.* 2022 doi: 10.1007/s00268-022-06856-8
11. Stamatis G., Leschber G., Schwarz B., Brintrup D.L., Flossdorf S., Passlick B., Hecker E., Kugler C., Eichhorn M., Krbek T., et al. Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm. *Lung Cancer.* 2022;172:108–116. doi: 10.1016/j.lungcan.2022.08.013.
12. Bedetti B., Bertolaccini L., Rocco R., Schmidt J., Solli P., Scarsi M. Segmentectomy versus lobectomy for stage I non-small cell lung cancer: A systematic review and meta-analysis. *J. Thorac. Dis.* 2017;9:1615–1623. doi: 10.21037/jtd.2017.05.79.
13. Shi Y., Wu S., Ma S., Lyu Y., Xu H., Deng L., Chen X. Comparison Between Wedge Resection and Lobectomy/Segmentectomy for Early-Stage Non-small Cell Lung Cancer: A Bayesian Meta-analysis and Systematic Review. *Ann. Surg. Oncol.* 2022;29:1868–1879. doi: 10.1245/s10434-021-10857-7.
14. Kearney D.J., Lee T.H., Reilly J.J., DeCamp M.M., Sugarbaker D. J Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. *Chest.* 1994;105:753–759. doi: 10.1378/chest.105.3.753.
15. Cukic V. Preoperative prediction of lung function in pneumonectomy by spirometry and lung perfusion scintigraphy. *Acta Inform. Med.* 2012;20:221–225. doi: 10.5455/aim.2012.20.221-225.
16. Mathew B., Nag S., Agrawal A., Ranganathan P., Purandare N.C., Shah S., Puranik A., Rangarajan V. Comparison of predicted postoperative forced expiratory volume in the first second (FEV1) using lung perfusion scintigraphy with observed forced expiratory volume in the first second (FEV1) post lung resection. *World J. Nucl. Med.* 2020;19:131–136. doi: 10.4103/wjnm.WJNM_59_19.